<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198482</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 20-13</org_study_id>
    <secondary_id>2014-000477-39</secondary_id>
    <nct_id>NCT02198482</nct_id>
  </id_info>
  <brief_title>Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) in&#xD;
      Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid&#xD;
      Leukemia (AML)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a randomized, Phase II, open label multi-center trial in adult patients with&#xD;
      newly diagnosed AML or high-risk MDS as defined in the inclusion/exclusion criteria.&#xD;
&#xD;
      An initial safety run-in study will be performed administering intensive induction therapy&#xD;
      consisting of daunorubicin and cytarabine with the study drug volasertib administered prior&#xD;
      or after chemotherapy, as well as consolidation therapy consisting of intermediate-dose&#xD;
      cytarabine with the study drug volasertib administered prior or after chemotherapy. After&#xD;
      establishing the volasertib dose, the randomized Phase II portion of the trial will begin:&#xD;
&#xD;
      Patients will be equally randomized to DA (daunorubicin, cytarabine), V-DA (volasertib&#xD;
      administered prior to daunorubicin, cytarabine), and DA-V (volasertib administered after&#xD;
      daunorubicin, cytarabine). All patients will receive a second induction cycle with reduced&#xD;
      daunorubicin and cytarabine doses. Patients refractory to the first induction cycle and&#xD;
      patients not achieving a CR/CRi after two induction cycles will be off-study and followed up.&#xD;
&#xD;
      Patients in CR/CRi after induction therapy will proceed to consolidation therapy.&#xD;
      Consolidation will be stratified based on the genetic risk profile (according to ELN&#xD;
      criteria) and patient-related factors (e.g., age, HCT-CI, comorbidities, patient wish).&#xD;
      Patients with a favorable genetic risk profile and those patients considered ineligible for&#xD;
      allogeneic HCT will receive repetitive cycles of consolidation according to initial&#xD;
      randomization, either MiDAC, V-MiDAC (volasertib administered prior to cytarabine), or&#xD;
      MiDAC-V (volasertib administered after cytarabine). All other patients are assigned to&#xD;
      allogeneic HCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    development program of study drug volasertib was stopped by Boehringer Ingelheim due to&#xD;
    manufacturing problems&#xD;
  </why_stopped>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete remission (CR) and CR with incomplete blood count recovery (CRi)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>High-risk Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Daunorubicin, Cytarabine (DA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DA&#xD;
Induction I:&#xD;
Daunorubicin 60 mg/m² i.v., d 1-3&#xD;
Cytarabine 100 mg/m² cont. i.v., d 1-7&#xD;
Induction II:&#xD;
Daunorubicin 50 mg/m² i.v. d 1-3&#xD;
Cytarabine 100 mg/m² cont. i.v., d 1-5&#xD;
Consolidation therapy:&#xD;
Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).&#xD;
Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (&gt;60 yrs): 8 mg/m2 by i.v. infusion on day 1.&#xD;
Intermediate-dose cytarabine:&#xD;
Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (&gt;60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volasertib, Daunorubicin, Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VDA&#xD;
Induction I&#xD;
Volasertib i.v., d1&#xD;
Daunorubicin 60 mg/m² i.v., d 2-4&#xD;
Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II&#xD;
Volasertib i.v., d1&#xD;
Daunorubicin 50 mg/m² i.v. d 2-4&#xD;
Cytarabine 100 mg/m² cont. i.v., d 2-6&#xD;
Consolidation therapy:&#xD;
Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).&#xD;
Volasertib i.v., d1&#xD;
Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (&gt;60 yrs): 8 mg/m2 by i.v. on day 2.&#xD;
Intermediate-dose cytarabine:&#xD;
Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (&gt;60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daunorubicin, Cytarabine, Volasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAV&#xD;
Induction I&#xD;
Volasertib i.v., d7&#xD;
Daunorubicin 60 mg/m² i.v., d 1-3&#xD;
Cytarabine 100 mg/m² i.v., d 1-7 Induction II&#xD;
Volasertib i.v., d5&#xD;
Daunorubicin 50 mg/m² i.v. d 1-3&#xD;
Cytarabine 100 mg/m² cont. i.v., d 1-5&#xD;
Consolidation therapy:&#xD;
Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).&#xD;
Volasertib i.v., d4&#xD;
Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (&gt;60 yrs): 8 mg/m2 by i.v. on day 1.&#xD;
Intermediate-dose cytarabine:&#xD;
Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (&gt;60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volasertib</intervention_name>
    <arm_group_label>Daunorubicin, Cytarabine, Volasertib</arm_group_label>
    <arm_group_label>Volasertib, Daunorubicin, Cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Daunorubicin, Cytarabine (DA)</arm_group_label>
    <arm_group_label>Daunorubicin, Cytarabine, Volasertib</arm_group_label>
    <arm_group_label>Volasertib, Daunorubicin, Cytarabine</arm_group_label>
    <other_name>ARA-cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <arm_group_label>Daunorubicin, Cytarabine (DA)</arm_group_label>
    <arm_group_label>Daunorubicin, Cytarabine, Volasertib</arm_group_label>
    <arm_group_label>Volasertib, Daunorubicin, Cytarabine</arm_group_label>
    <other_name>Daunoplastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <arm_group_label>Daunorubicin, Cytarabine (DA)</arm_group_label>
    <arm_group_label>Daunorubicin, Cytarabine, Volasertib</arm_group_label>
    <arm_group_label>Volasertib, Daunorubicin, Cytarabine</arm_group_label>
    <other_name>Novantron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with confirmed diagnosis of acute myeloid leukemia (AML) or related precursor&#xD;
             neoplasm, or acute leukemia of ambiguous lineage according to the current World Health&#xD;
             Organization (WHO) classification, or patients with myelodysplastic syndrome (MDS)&#xD;
             classified as refractory anemia with excess blasts-2 (RAEB-2)&#xD;
&#xD;
          -  Consent for a genetic assessment in AMLSG central laboratory&#xD;
&#xD;
          -  Patients considered eligible for intensive chemotherapy&#xD;
&#xD;
          -  ECOG performance status of ≤ 2&#xD;
&#xD;
          -  Age &gt;= 18; there is no upper age limit&#xD;
&#xD;
          -  No prior chemotherapy for acute leukemia except hydroxyurea for up to 5 days during&#xD;
             the diagnostic screening phase; patients may have received prior therapy for&#xD;
             myelodysplastic syndrome.&#xD;
&#xD;
          -  Non-pregnant and non-nursing. Due to the teratogenic potential of volasertib in&#xD;
             humans, pregnant or nursing patients may not be enrolled. Women of childbearing&#xD;
             potential (WOCBP) must have a negative serum or urine pregnancy test within a&#xD;
             sensitivity of at least 25 mIU/mL within 72 hours prior to registration. Women of&#xD;
             child-bearing potential must either commit to continued abstinence from heterosexual&#xD;
             intercourse or begin TWO acceptable methods of birth control - one highly effective&#xD;
             method (e.g., IUD, hormonal, tubal ligation, or partner's vasectomy), and one&#xD;
             additional effective method (e.g., latex condom, diaphragm, or cervical cap) for 6&#xD;
             months after therapy is stopped. &quot;Women of childbearing potential&quot; is defined as a&#xD;
             sexually active mature woman who has not undergone a hysterectomy or who has had&#xD;
             menses at any time in the preceding 24 consecutive months.&#xD;
&#xD;
          -  Men must agree not to father a child and must use a latex condom during any sexual&#xD;
             contact with women of childbearing potential while receiving therapy and for 6 months&#xD;
             after therapy is stopped, even if they have undergone a successful vasectomy&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia exhibiting t(15;17)(q22;q12); PML-RARA, or&#xD;
             with variant translocations&#xD;
&#xD;
          -  Prior treatment with volasertib or any other PLK1 inhibitor&#xD;
&#xD;
          -  Performance status WHO &gt;2 (see Appendix I)&#xD;
&#xD;
          -  Patients with ejection fraction &lt;50% by echocardiography within 14 days of day 1&#xD;
&#xD;
          -  QTcF prolongation &gt;470 ms or QT prolongation deemed clinically relevant by the&#xD;
             investigator (e.g., congenital long QT syndrome). The QTcF will be calculated as the&#xD;
             mean of 3 ECGs taken at screening.&#xD;
&#xD;
          -  Any clinically significant, advanced or unstable disease or history of that may&#xD;
             interfere with primary or secondary variable evaluations or put the patient at special&#xD;
             risk, such as:&#xD;
&#xD;
               -  creatinine &gt;1.5x upper normal serum level;&#xD;
&#xD;
               -  total bilirubin, AST or AP &gt;2.5x upper normal serum level;&#xD;
&#xD;
               -  heart failure NYHA III/IV,&#xD;
&#xD;
               -  uncontrolled hypertension,&#xD;
&#xD;
               -  unstable angina,&#xD;
&#xD;
               -  serious cardiac arrhythmia;&#xD;
&#xD;
               -  severe obstructive or restrictive ventilation disorder&#xD;
&#xD;
               -  uncontrolled infection&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancers. Patients are not considered to have a &quot;currently active&quot; malignancy, if they&#xD;
             have completed therapy and are considered by their physician to be at less than 30%&#xD;
             risk of relapse within one year.&#xD;
&#xD;
          -  Severe neurological or psychiatric disorder interfering with ability of giving an&#xD;
             informed consent&#xD;
&#xD;
          -  Known or suspected active alcohol or drug abuse&#xD;
&#xD;
          -  Known positive for HIV, active HBV, HCV, or hepatitis A infection&#xD;
&#xD;
          -  Hematologic disorder independent of leukemia&#xD;
&#xD;
          -  No consent for registration, storage and processing of the individual disease&#xD;
             characteristics and course as well as information of the family physician and/or other&#xD;
             physicians involved in the treatment of the patient about study participation.&#xD;
&#xD;
          -  No consent for biobanking.&#xD;
&#xD;
          -  Current participation in any other interventional clinical study within 30 days before&#xD;
             the first administration of the investigational product or at any time during the&#xD;
             study&#xD;
&#xD;
          -  Breast feeding women or women with a positive pregnancy test at Screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Döhner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMLSG Clinical Trials Office</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Paschka, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Hospital Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Hospital Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Hospital Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Berlin Campus Virchow Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum-Langendeer</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Essen, Protestant Hospital Essen-Werden</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Hospital St. Franziskus</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Frankfurt-Höchst</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Care Unit Osthessen</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelm-Anton-Hospital Goch</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Hospital Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Hanau</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KRH Hospital Siloah-Oststadt-Heidehaus</name>
      <address>
        <city>Hannover</city>
        <zip>30459</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Hospital Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Hospital Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lippe-Lemgo</name>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Johannes Gutenberg Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Hospital Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch-Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Schwabing</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital rechts der Isar München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Hospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Barmherzige Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>July 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Hartmut Doehner</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>Volasertib</keyword>
  <keyword>High-risk Myelodysplastic Syndrome (MDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

